The compensatory strategies employed by individuals with autism spectrum disorder might be a barrier to an official, timely diagnosis of autism, and might have negative consequences on individual’s mental health and well-being.
Top-down regulatory mechanisms influenced whether or not children with autism spectrum disorder expressed atypical behavioral responses to sensory stimuli.
The FDA has granted Fast Track status to the microbiota transfer therapy, Full-Spectrum Microbiota (FSM), for the treatment of children with autism spectrum disorder.
In neonates, having a first-degree relative with autism spectrum disorder was associated with higher levels of dysmaturation of interconnected regions that process higher-order social information.
